Evidence map›Paper›PMID 38302137›Full record

ArticleJournal of psychiatry & neuroscience : JPN

Permissive epigenetic regulatory mechanisms at the histone level are enhanced in postmortem dorsolateral prefrontal cortex of individuals with schizophrenia.

Oihane Martínez-Peula, Benito Morentin, Luis F Callado, J Javier Meana, Guadalupe Rivero, Alfredo Ramos-Miguel

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychiatry & neuroscience : JPN. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Oihane Martínez-PeulaFrom the Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain (Martínez-Peula, Callado, Meana, Rivero, Ramos-Miguel); Section of Forensic Pathology, Basque Institute of Legal Medicine, Bilbao, Spain (Morentin); the Biobizkaia Health Research Institute, Barakaldo, Spain ( Morentin, Callado, Meana, Rivero, Ramos-Miguel); and the Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, ISCIII, Spain (Callado, Meana, Rivero, Ramos-Miguel).
Benito MorentinFrom the Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain (Martínez-Peula, Callado, Meana, Rivero, Ramos-Miguel); Section of Forensic Pathology, Basque Institute of Legal Medicine, Bilbao, Spain (Morentin); the Biobizkaia Health Research Institute, Barakaldo, Spain ( Morentin, Callado, Meana, Rivero, Ramos-Miguel); and the Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, ISCIII, Spain (Callado, Meana, Rivero, Ramos-Miguel).
Luis F CalladoFrom the Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain (Martínez-Peula, Callado, Meana, Rivero, Ramos-Miguel); Section of Forensic Pathology, Basque Institute of Legal Medicine, Bilbao, Spain (Morentin); the Biobizkaia Health Research Institute, Barakaldo, Spain ( Morentin, Callado, Meana, Rivero, Ramos-Miguel); and the Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, ISCIII, Spain (Callado, Meana, Rivero, Ramos-Miguel).
J Javier MeanaFrom the Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain (Martínez-Peula, Callado, Meana, Rivero, Ramos-Miguel); Section of Forensic Pathology, Basque Institute of Legal Medicine, Bilbao, Spain (Morentin); the Biobizkaia Health Research Institute, Barakaldo, Spain ( Morentin, Callado, Meana, Rivero, Ramos-Miguel); and the Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, ISCIII, Spain (Callado, Meana, Rivero, Ramos-Miguel).
Guadalupe RiveroFrom the Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain (Martínez-Peula, Callado, Meana, Rivero, Ramos-Miguel); Section of Forensic Pathology, Basque Institute of Legal Medicine, Bilbao, Spain (Morentin); the Biobizkaia Health Research Institute, Barakaldo, Spain ( Morentin, Callado, Meana, Rivero, Ramos-Miguel); and the Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, ISCIII, Spain (Callado, Meana, Rivero, Ramos-Miguel) guadalupe.rivero@ehu.eus.
Alfredo Ramos-MiguelFrom the Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain (Martínez-Peula, Callado, Meana, Rivero, Ramos-Miguel); Section of Forensic Pathology, Basque Institute of Legal Medicine, Bilbao, Spain (Morentin); the Biobizkaia Health Research Institute, Barakaldo, Spain ( Morentin, Callado, Meana, Rivero, Ramos-Miguel); and the Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, ISCIII, Spain (Callado, Meana, Rivero, Ramos-Miguel).
BioCruces Health research Institute · ESInstituto de Salud Carlos III · ESCentro de Investigación Biomédica en Red de Salud Mental · ESUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSusceptibility to schizophrenia is determined by interactions between genes and environment, possibly via epigenetic mechanisms. Schizophrenia has been associated with a restrictive epigenome, and histone deacetylase (HDAC) inhibitors have been postulated as coadjuvant agents to potentiate the efficacy of current antipsychotic drugs. We aimed to evaluate global histone posttranslational modifications (HPTMs) and HDAC expression and activity in the dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia.

methodsWe used postmortem DLPFC samples of individuals with schizophrenia and controls matched for sex, age, and postmortem interval. Schizophrenia samples were classified into antipsychotic-treated or antipsychotic-free subgroups according to blood toxicology. Expression of HPTMs and HDAC was quantified by Western blot. HDAC activity was measured with a fluorometric assay.

resultsH3K9ac, H3K27ac, and H3K4me3 were globally enhanced in the DLPFC of individuals with schizophrenia (+24%-42%, LIMITATIONS: Special care was taken to control the effect of confounding factors: age, sex, postmortem interval, and storage time. However, replication studies in bigger cohorts might strengthen the association between permissive HPTMs and schizophrenia.

conclusionWe found global HPTM alterations consistent with an aberrantly permissive epigenome in schizophrenia. Further studies to elucidate the significance of enhanced permissive HPTMs in schizophrenia and its association with the mechanism of action of antipsychotic drugs are encouraged.

Indexed as

Antipsychotic AgentsSchizophreniaDorsolateral Prefrontal CortexEpigenesis, GeneticHistonesHumansPrefrontal CortexAntipsychotic AgentsHistones

Identifiers

PMID38302137
PMCPMC10843339
OpenAlexW4391435448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.